Pressefach: Roche Diagnostics GmbH

Roche Diagnostics Purchases Microarray Instrument and Accessory Assets from BioMicro Systems

(PresseBox) Madison, WI, USA, 11.03.2010, Roche Diagnostics (SIX: RO, ROG; OTCQX: RHHBY) has purchased assets from BioMicro Systems for all products associated with the Roche NimbleGen microarray workflow. These assets consist of key instrumentation in the comprehensive Roche NimbleGen microarray workflow including the NimbleGen Hybridization Systems (both 4- and 12bay models). Also included in this purchase are array accessories covering all mixers designed for the Roche NimbleGen highdensity microarray portfolio. Roche Diagnostics will continue to provide global sales, service, and support for all products in the NimbleGen microarray workflows.

With the purchase of these assets, Roche Diagnostics will transfer the manufacturing capabilities for the above products to an inhouse manufacturing facility. According to Andreas Görtz, VP of Marketing at Roche NimbleGen, 'The acquired products are integral to the high quality data the NimbleGen array workflow provides researchers worldwide. Acquiring these assets will allow Roche complete control over the production, support and service of these products to ensure continued timely distribution, full support and the high level of service our customers have grown to expect from Roche."

For more information on Roche NimbleGen products, visit www.nimblegen.com

About Roche Diagnostics GmbH

Headquartered in Basel, Switzerland, Roche is a leader in researchfocused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in invitro diagnostics, tissuebased cancer diagnostics and a pioneer in diabetes management. Roche's personalised healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2009, Roche had over 80'000 employees worldwide and invested almost 10 billion Swiss francs in R&D. The Group posted sales of 49.1 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information: www.roche.com.

Further press release of this company

• 15.02.2012 - Neue Forschungsergebnisse zur medikamenteninduzierten Rezeptoraktivität...
• 15.02.2012 - New Findings in Drug-Induced Receptor Activity Using Roche's...
• 15.02.2012 - Roche unterstützt den Smithsonian National Zoo mit einem Next-Generation-Sequenziergerät...
• 09.02.2012 - Roches xCELLigence Cardio Instrument misst Schlagrhythmus und...
• 09.02.2012 - Roche's xCELLigence Cardio Instrument Used to Detect Beating...
• 08.02.2012 - Roche Supports the Smithsonian's National Zoo with Next-Generation...